The Methodist Hospital Research Institute in Houston has received a four-year R01 award totaling USD 2,469,932 from the National Institute of Allergy and Infectious Diseases to investigate the activation mechanisms and immune functions of gasdermin C (GSDMC), a member of the gasdermin protein family implicated in innate immune regulation and inflammatory cell death.
The grant, administered under project number 1R01AI190307-01A1, runs from April 2026 through March 2031 and lists Reinhard Hinterleitner and Yi-Nan Gong as principal investigators. The work centers on unpublished data in which the team identified a protease capable of cleaving both human and murine GSDMC, producing an N-terminal fragment that behaves differently from activated fragments of other gasdermin family members.
The scientific premise distinguishes GSDMC from its paralogs GSDMA, GSDMB, GSDMD, and GSDME, all of which drive pyroptosis — a form of programmed necrotic cell death — upon protease-mediated cleavage. The GSDMC N-terminal fragment generated by the newly identified protease does not localize to the plasma membrane and does not effectively promote pyroptosis. Instead, preliminary data indicate it targets intracellular organelles and amplifies type-2 immune responses in animal models, a function unrelated to pore formation or cytokine release mechanisms associated with other gasdermins.
That distinction positions GSDMC as a potential upstream regulator of pathways implicated in asthma, fibrosis, and allergic disease — areas currently dominated by cytokine-targeting biologics. The identification of a specific activating protease also introduces a possible entry point for therapeutic modulation. The work remains early-stage, but reflects growing interest in expanding gasdermin biology beyond cell death and into broader immune regulation.
Spot something wrong? Report an issue with this article